

## Correction

---

### **Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study**

In this article (Clin Cancer Res 2009;15:5584–90), which published in the September 1, 2009, issue of *Clinical Cancer Research* (1), in the Results section, General subsection, the third sentence should read, as follows: In addition, 15 patients received 124 cycles of mapatumumab monotherapy (median, 6; range, 2-48). Also, in the Results section, Pharmacokinetics subsection, first sentence of the last paragraph should read, as follows: Mean (with 95% confidence interval) exposure in cycles 1 and 2, as measured by Area Under the Curve  $C_0$ ,  $AUC_{0-\infty}$ , or  $AUC_{last}$  for gemcitabine, 2-difluoro-2-deoxyuridine, and cisplatin-derived unbound platinum is summarized by cohort in Supplementary Table S2.

### **Reference**

1. Mom CH, Verweij J, Oldenhuis CNAM, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009;15:5584–90.

---

Published OnlineFirst 10/27/09.  
© 2009 American Association for Cancer Research.  
doi:10.1158/1078-0432.CCR-15-21-COR1

# Clinical Cancer Research

## Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study

*Clin Cancer Res* Published OnlineFirst October 27, 2009.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1078-0432.CCR-15-21-COR1](https://doi.org/10.1158/1078-0432.CCR-15-21-COR1)

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/early/2009/10/26/1078-0432.CCR-15-21-COR1.citation>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.